SAFETY AND EFFICACY OF INTRAVENTRICULAR 131I-LABELED MONOCLONAL ANTIBODY 8H9 TARGETING THE SURFACE GLYCOPROTEIN B7-H3

被引：0
|
作者：
Kramer, Kim [1 ]
Kushner, Brian [1 ]
Modak, Shakeel [1 ]
Taskar, Neeta Pandit [1 ]
Tomlinson, Ursula [1 ]
Donzelli, Maria [1 ]
Wolden, Suzanne [1 ]
Zanzonico, Pat [1 ]
Humm, John [1 ]
Haque, Sofia [1 ]
Souweidane, Mark [1 ]
Greenfield, Jeffrey [1 ]
Basu, Ellen [1 ]
Roberts, Stephen [1 ]
Carrasquillo, Jorge [1 ]
Lewis, Jason [1 ]
Lyashckenko, Serge [1 ]
Larson, Steven [1 ]
Cheung, Nai-Kong [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
NEURO-ONCOLOGY | 2018年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IMMU-05
引用
收藏
页码：99 / 99
页数：1
相关论文
共 50 条
  • [21] Radioimmunotherapy Targeting B7-H3 in situ glioma models enhanced antitumor efficacy by Reconstructing the tumor microenvironment
    Zheng, Meng
    Wang, Yan
    Fu, Fengqing
    Zhang, Kaijie
    Wang, Yanan
    Zhao, Shandong
    Liu, Qingfeng
    Mu, Huiwen
    Zhang, Xueguang
    Miao, Liyan
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2023, 19 (13): : 4278 - 4290
  • [22] PHASE 1 STUDY OF INTRAVENTRICULAR 131I-OMBURTAMAB TARGETING B7H3 (CD276)-EXPRESSING CNS MALIGNANCIES
    Modak, Shakeel
    Pandit Taskar, Neeta
    Kushner, Brian
    Zanzonico, Pat
    Humm, John
    Donzelli, Maria
    Lewis, Jason
    Lyashchenko, Serge
    Chu, Bae
    Larson, Stephen
    Cheung, Nai Kong
    Kramer, Kim
    PEDIATRIC BLOOD & CANCER, 2022, 69
  • [23] Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies
    Kim Kramer
    Neeta Pandit-Taskar
    Brian H. Kushner
    Pat Zanzonico
    John L. Humm
    Ursula Tomlinson
    Maria Donzelli
    Suzanne L. Wolden
    Sophia Haque
    Ira Dunkel
    Mark M. Souweidane
    Jeffrey P. Greenfield
    Satish Tickoo
    Jason S. Lewis
    Serge K. Lyashchenko
    Jorge A. Carrasquillo
    Bae Chu
    Christopher Horan
    Steven M. Larson
    Nai-Kong V. Cheung
    Shakeel Modak
    Journal of Hematology & Oncology, 15
  • [24] Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies
    Kramer, Kim
    Pandit-Taskar, Neeta
    Kushner, Brian H.
    Zanzonico, Pat
    Humm, John L.
    Tomlinson, Ursula
    Donzelli, Maria
    Wolden, Suzanne L.
    Haque, Sophia
    Dunkel, Ira
    Souweidane, Mark M.
    Greenfield, Jeffrey P.
    Tickoo, Satish
    Lewis, Jason S.
    Lyashchenko, Serge K.
    Carrasquillo, Jorge A.
    Chu, Bae
    Horan, Christopher
    Larson, Steven M.
    Cheung, Nai-Kong V.
    Modak, Shakeel
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [25] RADIOIMMUNOGUIDED SURGERY IN GASTRIC-CANCER USING 131-I LABELED MONOCLONAL-ANTIBODY 3H11
    XU, GW
    ZHANG, MY
    LIU, BG
    LI, ZF
    LIN, BH
    XU, XB
    JIN, ML
    LI, JY
    WU, J
    DONG, ZW
    SEMINARS IN SURGICAL ONCOLOGY, 1994, 10 (02): : 88 - 94
  • [26] Bispecific antibody targeting both B7-H3 and PD-L1 exhibits superior antitumor activities
    Hua-ying Li
    Yi-li Chen
    Xiang-nan Deng
    Huan-huan Li
    Jie Tan
    Guo-jian Liu
    Yu-juan Zheng
    Min Pei
    Kai-ting Peng
    Li-li Yue
    Xiao-jia Chen
    Yu Liu
    Yong-shan Zhao
    Chun-he Wang
    Acta Pharmacologica Sinica, 2023, 44 : 2322 - 2330
  • [27] Bispecific antibody targeting both B7-H3 and PD-L1 exhibits superior antitumor activities
    Li, Hua-ying
    Chen, Yi-li
    Deng, Xiang-nan
    Li, Huan-huan
    Tan, Jie
    Liu, Guo-jian
    Zheng, Yu-juan
    Pei, Min
    Peng, Kai-ting
    Yue, Li-li
    Chen, Xiao-jia
    Liu, Yu
    Zhao, Yong-shan
    Wang, Chun-he
    ACTA PHARMACOLOGICA SINICA, 2023, 44 (11) : 2322 - 2330
  • [28] Preclinical development of a duocarmycin-based antibody-drug conjugate targeting B7-H3 for solid cancer
    Son, Thomas
    Scribner, Juniper A.
    Hooley, Jeff
    Chiechi, Michael
    Li, Pam
    Hotaling, Timothy E.
    De Costa, Anushka
    Chen, Yan
    Chen, Francine
    Barat, Bhaswati
    Ciccarone, Valentina
    Gaynutdinov, Timur
    Tamura, James
    Koenig, Scott
    Johnson, Syd
    Moore, Paul A.
    Bonvini, Ezio
    Loo, Deryk
    CANCER RESEARCH, 2017, 77
  • [29] Targeting B7-H3 in prostate cancer: Phase 2 trial in localized prostate cancer using the anti-B7-H3 antibody enoblituzumab, with biomarker correlatives.
    Shenderov, Eugene
    De Marzo, Angelo M.
    Lotan, Tamara L.
    Wang, Hao
    Lim, Su Jin
    Allaf, Mohamad E.
    Moore, Paul A.
    Chen, Francine
    Sorg, Kristina
    White, Andrew M.
    Hudson, Briana
    Fields, Paul A.
    Hu, Shaohui
    Denmeade, Samuel R.
    Pienta, Kenneth J.
    Pavlovich, Christian P.
    Drake, Charles G.
    Pardoll, Drew M.
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] Preclinical development of a next generation antibody drug conjugate (ADC) targeting B7-H3 for treatment of solid tumors
    Xu, Jian
    Zong, Qing
    Wang, Wei
    Liu, Qigang
    Stann, Sasha
    Cai, Jiaqiang
    CANCER RESEARCH, 2023, 83 (07)
12345